The Toxicology Investigators Consortium Case Registry-the 2016 Experience
- PMID: 28766237
- PMCID: PMC5570732
- DOI: 10.1007/s13181-017-0627-3
The Toxicology Investigators Consortium Case Registry-the 2016 Experience
Abstract
The Toxicology Investigators Consortium (ToxIC) Case Registry was established by the American College of Medical Toxicology in 2010. The Registry contains data from participating sites with the agreement that all bedside medical toxicology consultations will be entered. Currently, 83% of accredited medical toxicology fellowship programs in the USA participate. The Registry continues to grow each year, and as of 31 December 2016, a new milestone was reached, with more than 50,000 cases reported since its inception. The objective of this seventh annual report is to summarize the Registry's 2016 data and activity with its additional 8529 cases. Cases were identified for inclusion in this report by a query of the ToxIC database for any case entered from 1 January to 31 December 2016. Detailed data was collected from these cases and aggregated to provide information which includes the following: demographics (age, gender, race, ethnicity, HIV status), reason for medical toxicology evaluation (intentional pharmaceutical exposure, envenomation, withdrawal from a substance), agent and agent class, clinical signs and symptoms (vital sign abnormalities, organ system dysfunction), treatments and antidotes administered, fatality and life support withdrawal data. Fifty percent of cases involved females, and adults aged 19-65 were the most commonly reported. There were 86 patients (1.0%) with HIV-positive status known. Non-opioid analgesics were the most commonly reported agent class, with acetaminophen the most common agent reported. There were 126 fatalities reported in 2016 (1.5% of cases). Major trends in demographics and exposure characteristics remained similar overall with past years' reports. While treatment interventions were commonly required, fatalities were rare.
Keywords: Epidemiology; Medical toxicology; Overdose; Poisonings.
Conflict of interest statement
Funding
ToxIC was supported by a continuation of a grant from the US National Institutes of Health on cardiovascular drug toxicity, a new contract with the US Food and Drug Administration, and the continuation of unrestricted grant support from BTG International, which was used to support the North American Snakebite Registry.
Conflicts of Interest
None
Previous Presentation of Data
None
Funding Sources
This study received funding from the NIH National Institute on Drug Abuse 1R56DA38366, and 1R01DA037317-01, a data sharing contract with the U.S. Food and Drug Administration, and BTG International Inc.
References
-
- Judge BS, Ouellette LM, VandenBerg M, Riley BD, Wax PM, On behalf of the ACMT Toxicology Investigators Consortium (ToxIC) Utilization of observation units for the care of poisoned patients: trends from the Toxicology Investigators Consortium Case Registry. J Med Toxicol. 2016;12:111–120. doi: 10.1007/s13181-015-0498-4. - DOI - PMC - PubMed
-
- Riederer AM, Campleman SI, Carlson RG, Toxicology Investigators Consortium (ToxIC) et al. Acute poisonings from synthetic cannabinoids—50 US Toxicology Investigators Consortium registry sites, 2010–2015. MMWR. Morb Mortal Wkly Rep. 2016;65(27):692–695. doi: 10.15585/mmwr.mm6527a2. - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
